#35
Clinical Context
Background information relevant to the evolving cannabis medicine landscape.
Arizona’s lack of a legal THC impairment threshold creates evidentiary ambiguity in DUI prosecutions that clinicians should understand, as patients may face criminal consequences despite blood THC levels that do not reliably correlate with impairment. Clinicians treating patients involved in DUI cases or advising on cannabis use need to recognize that current biomarkers cannot definitively establish functional impairment, making officer observations and patient history critical to distinguishing between use and actual driving incapacity. This regulatory gap underscores the need for clinicians to counsel patients on the unpredictable legal risks of cannabis use before driving, particularly in jurisdictions without standardized impairment testing analogous to alcohol breathal
Arizona’s marijuana DUI enforcement lacks a legally established THC blood concentration threshold analogous to alcohol’s 0.08% standard, creating significant challenges in prosecuting cannabis-impaired driving cases that rely heavily on subjective officer observations and post-arrest blood testing. This regulatory gap means that drivers can be charged with cannabis-related DUI based primarily on behavioral assessments and circumstantial evidence rather than objective biomarkers, leading to inconsistent legal outcomes and uncertainty about what constitutes impairment under the law. For clinicians, this underscores the absence of reliable clinical standards linking blood THC levels to actual impairment, a limitation that extends to workplace drug testing and patient counseling about cannabis use and driving safety. The variability in THC pharmacokinetics between users, the poor correlation between blood THC and cognitive impairment, and the persistence of THC metabolites in the bloodstream long after impairment has resolved complicate both law enforcement and medical assessment of cannabis intoxication. Clinicians should counsel patients that blood THC levels do not reliably predict impairment and advise them that cannabis use followed by driving carries legal risk in Arizona regardless of whether objective impairment can be demonstrated, while also recognizing the scientific limitations in current impairment testing.
“We don’t have a reliable biomarker for cannabis impairment the way we do for alcohol, which means police officers and prosecutors are essentially guessing, and patients with legitimate medical use are at genuine legal risk based on presence rather than actual impairment. Until we develop better roadside assessment tools and establish evidence-based THC thresholds, these cases will remain scientifically indefensible, and that’s a problem for public safety and justice.”
? Arizona’s approach to cannabis-impaired driving highlights a critical gap in clinical practice: the absence of a standardized, validated threshold for THC blood concentration that reliably predicts impairment. Unlike alcohol with its well-established 0.08% standard, marijuana cases depend heavily on subjective officer observations and imprecise biomarkers that do not necessarily correlate with functional impairment, since THC levels can remain elevated long after intoxication has resolved. This creates a problematic situation where patients who use cannabis therapeutically or recreationally may be wrongly assessed as impaired, while the biological complexity of cannabinoid metabolism—influenced by frequency of use, individual tolerance, and route of administration—remains poorly understood by law enforcement and sometimes by clinicians themselves. Healthcare providers should be aware that patients may face legal consequences based on THC blood tests alone, and should counsel patients about the disconnect between blood levels and actual impairment,
💬 Join the Conversation
Have a question about how this applies to your situation?
Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers?
Join the forum discussion →
Have thoughts on this? Share it:
